Axon Enterprise, Inc $AXON Shares Bought by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. grew its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 23,900.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,440 shares of the biotechnology company’s stock after acquiring an additional 1,434 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Axon Enterprise were worth $818,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Benjamin Edwards Inc. boosted its holdings in shares of Axon Enterprise by 2.1% during the fourth quarter. Benjamin Edwards Inc. now owns 2,227 shares of the biotechnology company’s stock valued at $1,265,000 after acquiring an additional 46 shares during the period. Strs Ohio boosted its holdings in shares of Axon Enterprise by 12.9% during the fourth quarter. Strs Ohio now owns 39,287 shares of the biotechnology company’s stock valued at $22,312,000 after acquiring an additional 4,503 shares during the period. Caisse Des Depots ET Consignations acquired a new position in shares of Axon Enterprise during the fourth quarter valued at $218,000. PFA Pension Forsikringsaktieselskab acquired a new position in shares of Axon Enterprise during the fourth quarter valued at $23,145,000. Finally, Robertson Stephens Wealth Management LLC acquired a new position in shares of Axon Enterprise during the fourth quarter valued at $11,263,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Jennifer H. Mak sold 1,500 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeri Williams sold 157 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the sale, the director directly owned 1,159 shares of the company’s stock, valued at $567,910. The trade was a 11.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 13,855 shares of company stock valued at $7,109,828. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Performance

AXON stock opened at $402.31 on Monday. The company has a market capitalization of $32.41 billion, a P/E ratio of 264.68, a PEG ratio of 8.59 and a beta of 1.44. The company has a 50-day simple moving average of $454.05 and a 200 day simple moving average of $532.97. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.08 earnings per share. Sell-side analysts predict that Axon Enterprise, Inc will post 1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AXON has been the subject of several analyst reports. Weiss Ratings downgraded shares of Axon Enterprise from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. TD Cowen reduced their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Sixteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $749.63.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.